×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KALV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
08:03 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.
12/16
07:10 am
kalv
KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]
Medium
Report
KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]
12/16
07:00 am
kalv
KalVista Appoints Jeb Ledell as Chief Operating Officer
Medium
Report
KalVista Appoints Jeb Ledell as Chief Operating Officer
12/9
10:18 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/6
08:13 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
12/5
12:25 pm
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Low
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
12/5
06:42 am
kalv
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update [Yahoo! Finance]
12/5
06:30 am
kalv
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
Low
Report
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
Date
Time
Symbol
Company Name
Action
%Chg
12/5/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
BEAT
Report
-1.3%
kalvista pharmaceuticals, inc.
12/5/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
BEAT
Report
-1.3%
kalvista pharmaceuticals, inc.
12/5/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
BEAT
Report
-1.3%
kalvista pharmaceuticals, inc.
12/5/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
BEAT
Report
-1.3%
kalvista pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
07:08 am
kalv
Form 8-K KalVista Pharmaceuticals For: Dec 16
Medium
Report
Form 8-K KalVista Pharmaceuticals For: Dec 16
12/9
09:08 pm
kalv
Form 4 KalVista Pharmaceuticals For: Dec 06 Filed by: Palleiko Benjamin L
Low
Report
Form 4 KalVista Pharmaceuticals For: Dec 06 Filed by: Palleiko Benjamin L
12/5
04:17 pm
kalv
Form 8-K KalVista Pharmaceuticals For: Dec 05
Medium
Report
Form 8-K KalVista Pharmaceuticals For: Dec 05
12/5
04:08 pm
kalv
Form 10-Q KalVista Pharmaceuticals For: Oct 31
Medium
Report
Form 10-Q KalVista Pharmaceuticals For: Oct 31
11/27
08:46 pm
kalv
Form 4 KalVista Pharmaceuticals For: Nov 22 Filed by: Audhya Paul K.
Medium
Report
Form 4 KalVista Pharmaceuticals For: Nov 22 Filed by: Audhya Paul K.
11/27
08:44 pm
kalv
Form 4 KalVista Pharmaceuticals For: Nov 22 Filed by: Yea Christopher
Medium
Report
Form 4 KalVista Pharmaceuticals For: Nov 22 Filed by: Yea Christopher
11/26
04:52 pm
kalv
Form 4 KalVista Pharmaceuticals For: Nov 23 Filed by: Reid Laurence
Low
Report
Form 4 KalVista Pharmaceuticals For: Nov 23 Filed by: Reid Laurence
11/26
04:45 pm
kalv
Form 3 KalVista Pharmaceuticals For: Nov 23 Filed by: Reid Laurence
Low
Report
Form 3 KalVista Pharmaceuticals For: Nov 23 Filed by: Reid Laurence
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/9
Q1/2019 7/31/2019 EPS -0.420 ZacksConsensus -0.610 ActVsEst 0.190 - Beat
9.9%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
TOP News Decliners
3/10
Form 10-Q KalVista Pharmaceuticals For: Jan 31
-14.8%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: